Esperion Therapeutics, Inc. (NASDAQ:ESPR) a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, on 12 Aug 2014 provided ETC-1002 development program updates and financial results for the second quarter ended June 30, 2014. In July, company initiated enrollment in the Phase 2 ETC-1002-014 study in 144 patients … Continue reading Active Watch List : Esperion Therapeutics (NASDAQ:ESPR), Office Depot (NYSE:ODP), Universal Forest NASDAQ:UFPI), First Financial Bankshares (NASDAQ:FFIN), Eldorado (NYSE:EGO)